文献速递肝病消化道肿瘤与早癌

生活方式与胰高血糖素样肽-1受体激动剂在肥胖、2型糖尿病和脂肪性肝病减重中的作用

Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases.
PubMed 文献 · Aliment Pharmacol Ther · 2024-01-01

本文综述肥胖、2型糖尿病和代谢功能障碍相关脂肪性肝病(MASLD)的共同病理生理特征及减重策略。生活方式干预减重程度中等且可持续性有限,第一代抗肥胖药或限于短期或特定肥胖类型。部分GLP-1RA显著减少热量摄入和体重,利拉鲁肽和司美格鲁肽已获批治疗肥胖,且可减少经活检确诊MASLD者的肝脂肪含量和炎症。

要点

  • 生活方式干预减重程度中等且可持续性有限。
  • 利拉鲁肽和司美格鲁肽已获批用于治疗肥胖人群。
  • 部分GLP-1RA可减少经活检确诊MASLD者的肝脂肪含量和炎症。

核心结论

  • 某些GLP-1RA在诱导减重方面优于生活方式干预和第一代抗肥胖药,并显著改变了肥胖治疗格局,对脂肪性肝病有额外益处。

研究设计与样本

  • 广泛文献研究,描述生活方式调整、第一代抗肥胖药和GLP-1RA对肥胖、2型糖尿病和MASLD患者减重效果。

主要发现

  • 生活方式干预减重程度中等且可持续性有限。
  • 已获批的少数第一代抗肥胖药或限于短期使用,或限于某些形式的肥胖。
  • 部分GLP-1RA显著减少热量摄入和体重。
  • 利拉鲁肽和司美格鲁肽已获批用于治疗肥胖人群。
  • 利拉鲁肽和司美格鲁肽可减少经活检确诊MASLD者的肝脂肪含量和炎症。

关键数值与推荐

  • 利拉鲁肽和司美格鲁肽已获批用于治疗肥胖人群。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 可能的局限性包括不良反应、治疗依从性和持续性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The current obesity pandemic has given rise to associated comorbidities and complications, including type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD). During the last decade, certain glucagon-like peptide 1 receptor agonists (GLP-1RA), originally developed as antihyperglycemic drugs, also demonstrated efficacy for weight loss. AIMS: To review shared pathophysiologic features of common metabolic diseases and compare therapeutic strategies to reduce body weight and related complications. METHODS: We performed an extensive literature research to describe the effects of lifestyle modification, first-generation anti-obesity drugs, and GLP-1RA on weight loss in humans with obesity, type 2 diabetes and MASLD. RESULTS: Until recently, treatment of obesity has been limited to lifestyle modification, which offer moderate degree and sustainability of weight loss. The few approved first-generation anti-obesity drugs are either limited to short term use or to certain forms of obesity. Some GLP-1RA significantly decrease caloric intake and body weight. Liraglutide and semaglutide have therefore been approved for treating people with obesity. They also lead to a reduction of hepatic fat content and inflammation in people with biopsy-confirmed MASLD. Possible limitations comprise adverse effects, treatment adherence and persistence. CONCLUSION: Certain GLP-1RA are superior to lifestyle modification and first-generation anti-obesity drugs in inducing weight loss. They have therefore markedly changed the portfolio of obesity treatment with additional beneficial effects on steatotic liver disease.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Giannakogeorgou A, Roden M. Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases. Aliment Pharmacol Ther. 2024. PMID: 38813830. doi:10.1111/apt.17848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。